ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) is a
biopharmaceutical company focused on the development of targeted antiviral
therapies. The company’s leading product candidate, FV-100, is currently in
phase III clinical development for the treatment of shingles, as well as for
the prevention of debilitating shingles-associated pain known as post-herpetic
neuralgia (PHN). Additionally, ContraVir’s product pipeline includes CMX157,
which is scheduled to be evaluated in a phase II clinical study for the
treatment of hepatitis B virus in the coming months.
While there are already antivirals approved to treat the
viral infection underlying shingles, there are currently no approved antiviral
therapies for the prevention of PGN. According to a report by the National
Institute of Health, an estimated one million Americans suffer from shingles
each year, and more than 65 percent of those individuals suffer from PHN for 30
days or more. In some cases, PHN symptoms can persist for well over two years
if left untreated. Through the eventual commercialization of FV-100, ContraVir
will gain access to this critically underserved market segment within the
biopharmaceutical industry. In clinical trials, FV-100 demonstrated a
clinically meaningful 37 percent reduction in the incidence of PHN versus the
current standard of care.
In addition to FV-100, the company continues to make
clinical progress with CMX157. In June, ContraVir took a major step in the
development of CMX157 by partnering with the Baruch S. Blumberg Institute, the
non-profit research sister organization of the Hepatitis B Foundation, to
conduct a series of experiments with the company’s drug candidate.
Specifically, these tests will focus on comparing the relative anti-hepatitis B
activities of CMX157 with those of tenofovir, the current standard of care, in
order to determine if the candidate has unique attributes not previously
appreciated of other antiviral agents.
“The Blumberg Institute’s commitment to advancing new
therapies for hepatitis B make them an ideal research and development vehicle
for ContraVir,” James Sapirstein, chief executive officer of ContraVir, stated
in a news release. “This association will help advance our CMX157 candidate and
may further de-risk the development process going forward, as we prepare to
enter phase II clinical studies.”
For prospective shareholders, ContraVir’s considerable
developmental progress could foreshadow an opportunity to realize sustainable
returns moving forward. Following its uplisting to the NASDAQ Capital Market
earlier this year, the company is in a strong strategic position to capitalize
on improved visibility in the coming months. Look for ContraVir to leverage the
opportunities presented by this visibility in order to optimize market growth
as it continues toward the commercialization of its advanced product pipeline.
For more information, visit www.contravir.com
About
MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
